lisdexamfetamine
Adjunctive therapy • Brands: VYVANSE
Last reviewed: 2025-12-29
General information
- Class: Adjunctive therapy
- Common US brands: VYVANSE
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-29
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Prodrug stimulant converted to dextroamphetamine; increases dopamine and norepinephrine signaling.
Metabolism & Half‑life
- Metabolism: Enzymatic hydrolysis (blood) to dextroamphetamine
- Half‑life: Single-dose mean 11 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Vyvanse (lisdexamfetamine dimesylate) prescribing information — DailyMed (2025)
- Attention deficit hyperactivity disorder (NICE guideline NG87) — NICE (2018)
- Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents — Pediatrics (2019)
- Comparative efficacy and tolerability of medications for ADHD (systematic review and network meta-analysis) — Lancet Psychiatry (2018)